Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. reports company news around a clinical-stage oncology pipeline led by evorpacept, an investigational CD47 inhibitor designed to address a cancer immune-evasion signal. Updates commonly cover clinical data presentations, biomarker analyses involving CD47 expression, and studies of evorpacept combinations in HER2-positive cancers, including breast and gastric cancer settings.
The company also reports development activity for ALX2004, an EGFR-targeted antibody-drug conjugate for EGFR-expressing solid tumors. Other recurring updates include quarterly financial results, research and development spending, cash runway commentary, registered offerings of common stock and pre-funded warrants, leadership appointments, investor conference participation, and Nasdaq inducement equity grants.
ALX Oncology (NASDAQ: ALXO) reported Q1 2026 results and clinical updates on May 8, 2026. Key points: exploratory Phase 1b/2 data show durable responses with evorpacept + zanidatamab in ccHER2-positive, high CD47 patients; ASPEN-09-Breast topline for 80 patients expected mid-2027; ALX2004 safety data due 2H 2026.
Company completed a registered offering (gross $150.0M; net $140.4M) and held $169.1M cash and investments as of March 31, 2026, sufficient to fund operations through H1 2028.
ALX Oncology (NASDAQ: ALXO) reported Phase 1b/2 exploratory data showing evorpacept plus zanidatamab produced a confirmed objective response rate of 100% (5/5) in ccHER2-positive metastatic breast cancer patients with high CD47 expression (>20%).
High-CD47 patients had mPFS of 22.1 months and mDOR of 20.2 months; low-CD47 patients had mPFS of 3.4 months. A webcast on May 8 will review Q1 2026 results and trial data.
ALX Oncology (Nasdaq: ALXO) will present exploratory CD47 biomarker data from its Phase 1b/2 trial of evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer at ESMO Breast Cancer 2026 on May 7, 2026.
ALX will report Q1 2026 financial results on May 8, 2026, and host a conference call at 8:30 a.m. ET with guest speaker Dr. Sara Hurvitz. Topline analyses announced in January 2026 indicated responses concentrated in patients with higher CD47 expression.
ALX Oncology (Nasdaq: ALXO) granted an inducement stock option to Jeff Knight, Chief Development and Operating Officer, consisting of 800,000 shares on April 16, 2026.
The option has an exercise price of $1.68 (equal to the closing price on the grant date) and vests 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly thereafter under the 2025 Inducement Equity Incentive Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
ALX Oncology (NASDAQ: ALXO) appointed Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings more than 30 years of biopharma and oncology experience across clinical development, regulatory affairs, and operations.
The company said his hire aims to strengthen development capabilities ahead of expected catalysts for evorpacept and ALX2004 over the next 12–18 months and to support late‑stage development and commercialization readiness.
ALX Oncology (Nasdaq: ALXO) reported Q4 and full‑year 2025 results and a corporate update on Feb 27, 2026. Key clinical advances include biomarker‑driven evidence that CD47 overexpression predicts evorpacept activity, ASPEN‑09‑Breast enrollment and ALX2004 dose‑escalation progress. Financially, the company completed a $150.0M registered offering (net $140.4M) and held $48.3M cash at year‑end, extending runway through 1H 2028.
Upcoming milestones: full biomarker poster at ESMO Breast (May 7, 2026), ALX2004 safety data in 2H 2026, and ASPEN‑09 topline for 80 patients mid‑2027.
ALX Oncology (Nasdaq: ALXO) announced participation in three investor events in Q1 2026: Wells Fargo Executive Biotech Summit (one-on-one meetings, Feb 24-25, 2026, Lake Tahoe, CA), TD Cowen 46th Annual Health Care Conference (presentation, Mar 3, 2026, 9:10 AM EST, Boston, MA; webcast available), and UBS Biotech Summit (one-on-one meetings, Mar 10, 2026, Miami, FL).
The TD Cowen webcast will be accessible via the Investors section at www.alxoncology.com and replayed for up to 90 days.
ALX Oncology (Nasdaq: ALXO) will report fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026 before market open.
The company will host a teleconference and live audio webcast at 5:30am PT / 8:30am ET; a replay and corporate presentation will be archived on the investor section of the company website.
ALX Oncology (Nasdaq: ALXO) priced an underwritten offering to sell 76,979,112 shares of common stock and pre-funded warrants for 18,574,120 shares at $1.57 per share (pre-funded warrant price $1.569).
The offering is expected to close on or about Feb 2, 2026, with gross proceeds of approximately $150 million before expenses. Net proceeds are to fund continued clinical development of evorpacept and the ALX2004 program and for general corporate purposes.
ALX Oncology (Nasdaq: ALXO) reported exploratory Phase 1b/2 data showing CD47 expression predicts response to investigational CD47 inhibitor evorpacept combined with Ziihera (zanidatamab-hrii) in HER2-positive metastatic breast cancer. In nine centrally confirmed HER2-positive patients the combination produced a 56% confirmed objective response rate and median PFS of 7.4 months. The full biomarker analysis has been submitted for presentation at an upcoming scientific congress and reinforces prior ASPEN-06 gastric cancer findings linking CD47 expression to benefit.